E-mail us

Industry Shift: FDA Goes Vegan?

Approaching Drug Development With Finesse

In 2012, drug development specialists started an initiative to create predictive Oral Bioavailability Tools (OrBiTo). This initiative recognized the need to move away from random trial-and-error in vivo drug development by integrating more efficient in vitro and in silico methods.

At the end of 2022, President Joe Biden signed legislation formalizing this shift away from heavy in vivo reliance. New medications can now be approved by the U.S. Food and Drug Administration (FDA) without animal studies.Drug development is now trending away from animal studies

While it is recognized that animal studies will still play an important role in new drug research and approvals for the foreseeable future, this new legislation signals an industry-wide shift towards in silico studies that must be acknowledged.

Drug innovators looking for the most effective and efficient drug development pathway to bring promising molecules to market need to give careful consideration to the approach they choose.

Wasteful, prolonged trial-and-error methodologies for form and formulation are a thing of the past. Today's industry standard requires that drug developers guide development through a strategic approach, from lead compound optimization to first in human (FIH) clinical trials.

| "Smart preclinical development using established innovative tools saves time, money, and lives."

| Robert Wenslow, Ph.D., Co-Founder and VP of Business Development

A New Chapter in Drug Development

Better data, smarter analysis


Crystal Pharmatech moves molecule to medicine by adopting a constantly evolving approach that brings together cutting-edge AI capabilities, the most efficient in vitro platforms, and leading experts in API form and formulation.

The result of this approach is the revolutionary Mol2Med™ Developability Assessment, putting an end to outdated and inefficient guesswork.

The Mol2Med™ Developability Assessment is a dynamic, fit-for-purpose service that helps drug developers achieve a comprehensive understanding of their molecule’s potential for development.


Mol2Med™ Developability Assessment Workflow

With as little as 500mg of API and 4 weeks, Crystal Pharmatech offers a smarter path forward by:

Our Experience Becomes Your Competitive Advantage

Crystal Pharmatech R&D and Subject Matter Experts have decades of experience moving molecules to medicine.

The Mol2Med™ pathway offers specific next steps to reach all major milestones throughout drug development program - from lead compound selection to formulation development.

Crystal Pharmatech experts provide clear insights that help drug innovators:

Leading experts will ensure CMC is not limiting Tox and Phase I success while assessing later stage developability risks of API and drug product.

With cohesion between solid-state and formulation experts, drug innovators partnering with Crystal Pharmatech gain continuity and a goal-oriented approach throughout every stage of development.

For further information, follow and stay updated at the Crystal Pharmatech LinkedIn page.



Related Updates in Crystal Pharmatech

Contact Us
bd_global@crystalpharmatech.com +1-609-604-8303
Suite 500-B, 3000 Eastpark Blvd, Cranbury, New Jersey 08512, USA
6800 Kitimat Rd, Unit 1, Mississauga, Ontario, Canada L5N 5M1
Suite B4-101, Biobay, 218 Xinghu Street, Suzhou Industrial Park, Suzhou, China, 215123
Suite 500-B, 3000 Eastpark Blvd, Cranbury, New Jersey 08512, USA
bd_global@crystalpharmatech.com +1-609-604-8303